OPKO Health Takes 15% Equity Stake in Nicoya for China RAYALDEE Expansion
OPKO Health’s subsidiary EirGen Pharma gained a 15% equity stake in Nicoya in exchange for a revised tiered royalty and transfer-price schedule as it expands RAYALDEE commercialization across Greater China. The amendment preserves up to $115 million in milestone payments and targets regulatory approvals for China and related territories in 2027.
1. Equity Stake and Financial Terms
OPKO Health’s EirGen Pharma subsidiary acquired a 15% equity stake in Nicoya through issuance of Series A-2 Preferred Shares in exchange for a revised tiered royalty and transfer-price schedule. The deal maintains up to $115 million in development, regulatory, and sales-based milestone payments under the original agreement.
2. Greater China Commercial Strategy
The amended agreement expands the field of use for RAYALDEE® across Greater China, where it is already approved in Macau and is anticipated to secure regulatory approvals in mainland China and related territories by 2027. This region encompasses over 20 million adults with stage 3 or 4 chronic kidney disease, presenting a substantial market opportunity.
3. Strategic Implications for OPKO Health
Through EirGen, OPKO Health has established an integrated supply chain for RAYALDEE manufacturing and packaging, positioning the company to capture value from Nicoya’s commercialization efforts. The expanded collaboration aligns with OPKO Health’s strategy to extend its nephrology portfolio into high-growth Asian markets and participate in long-term revenue streams.